Hypochondroplasia
Drug research and approvals for hypochondroplasia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 5 studies of hypochondroplasia are recruiting on ClinicalTrials.gov, Health Canada has authorized 5 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 5
- Trials authorized in Canada: 5
- FDA orphan approvals: 0
- EU medicines: 0
- Prospective Longitudinal Multicentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaNCT07388966 · Not reported · SYSNAV · starts Feb 6, 2026
- A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsNCT07126262 · Phase 2 · BioMarin Pharmaceutical · starts Jul 30, 2025
- Prospective Clinical Assessment Study in Children With HypochondroplasiaNCT06410976 · Not reported · QED Therapeutics, a BridgeBio company · starts Jun 5, 2024
- A Multicenter Multinational Observational Study of Children With HypochondroplasiaNCT06212947 · Not reported · BioMarin Pharmaceutical · starts Nov 27, 2023
- Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)NCT05328050 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Sep 1, 2021
| Sep 23, 2026 | A phase 3, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of once-weekly navepegritide versus placebo in…Navepegritide | Ascendis Pharma | Pending |
| Dec 8, 2025 | Phase 2, open-label, long-term, extension (OLE) study of infigratinib, an fgfr 1-3-selective tyrosine kinase inhibitor, in children with hypochondroplasia:…Infigratinib (BGJ398) | Qed Therapeutics, Inc. | Ongoing |
| Jun 13, 2025 | A phase 3, open-label, long-term extension study to evaluate the safety and efficacy of vosoritide in children with hypochondroplasiaVoxzogo (bmn 111) | BioMarin Pharmaceutical | Ongoing |
| Mar 26, 2025 | A phase 2/3, multicenter, open-label phase followed by a double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib…Infigratinib | Qed Therapeutics, Inc. | Ongoing |
| Jul 12, 2024 | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of vosoritide in children with hypochondroplasia.Vosoritide | BioMarin Pharmaceutical | Ongoing |
| Jun 3, 2025 | InfigratinibTreatment of hypochondroplasia | QED Therapeutics, Inc | Designated |
| Aug 1, 2023 | VosoritideTreatment of hypochondroplasia | BioMarin Pharmaceutical Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA